• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.在识别晚期卵巢癌中最不适合细胞减灭术的患者时,减少猜测,增加证据:一种个体化手术管理的分诊算法。
Gynecol Oncol. 2020 Jun;157(3):572-577. doi: 10.1016/j.ygyno.2020.03.024. Epub 2020 Apr 1.
2
Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.采用基于证据的分诊算法降低高级别上皮性卵巢癌初次肿瘤细胞减灭术后 90 天死亡率。
Gynecol Oncol. 2019 Oct;155(1):58-62. doi: 10.1016/j.ygyno.2019.08.004. Epub 2019 Aug 8.
3
Validation of a risk-based algorithm to reduce poor operative outcomes after complex surgery for ovarian cancer.验证一种基于风险的算法,以降低卵巢癌复杂手术后不良手术结局的风险。
Int J Gynecol Cancer. 2023 Jan 3;33(1):83-88. doi: 10.1136/ijgc-2022-003799.
4
Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.梅奥分诊算法在个体化治疗晚期上皮性卵巢癌中的应用性能验证。
Gynecol Oncol. 2021 Aug;162(2):339-344. doi: 10.1016/j.ygyno.2021.06.003. Epub 2021 Jun 17.
5
Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.适当的分诊可进行积极的初次肿瘤细胞减灭术,其发病率和死亡率与化疗后间隔手术相当。
Gynecol Oncol. 2021 Mar;160(3):681-687. doi: 10.1016/j.ygyno.2020.12.026. Epub 2020 Dec 31.
6
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.一种多模态分诊算法,旨在提高接受原发性减瘤手术治疗晚期卵巢癌患者的细胞减灭术效果:纪念斯隆凯特琳癌症中心卵巢倡议团队。
Gynecol Oncol. 2020 Sep;158(3):608-613. doi: 10.1016/j.ygyno.2020.05.041. Epub 2020 Jun 6.
7
Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.晚期上皮性卵巢癌肿瘤减灭术中肠手术和造口形成后的临床特征和结局。
Int J Gynecol Cancer. 2019 Mar;29(3):585-592. doi: 10.1136/ijgc-2018-000154.
8
When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.当少即是多时:新辅助化疗后晚期卵巢癌间隔减瘤术的微创与剖腹手术比较。
J Minim Invasive Gynecol. 2019 Jul-Aug;26(5):902-909. doi: 10.1016/j.jmig.2018.09.765. Epub 2018 Sep 18.
9
Validation of the Integrated Prediction Model algorithm for outcome of cytoreduction in advanced ovarian cancer.高级卵巢癌肿瘤细胞减灭术结局的综合预测模型算法的验证。
Int J Gynecol Cancer. 2023 Jul 3;33(7):1077-1082. doi: 10.1136/ijgc-2022-004202.
10
Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.将机器人手术纳入新辅助化疗后卵巢癌的治疗管理中。
Int J Gynecol Cancer. 2019 Nov;29(9):1341-1347. doi: 10.1136/ijgc-2019-000413. Epub 2019 Oct 9.

引用本文的文献

1
Neglected Anatomical Areas in Ovarian Cancer: Significance for Optimal Debulking Surgery.卵巢癌中被忽视的解剖区域:对最佳肿瘤细胞减灭术的意义
Cancers (Basel). 2024 Jan 9;16(2):285. doi: 10.3390/cancers16020285.
2
Validation of a risk-based algorithm to reduce poor operative outcomes after complex surgery for ovarian cancer.验证一种基于风险的算法,以降低卵巢癌复杂手术后不良手术结局的风险。
Int J Gynecol Cancer. 2023 Jan 3;33(1):83-88. doi: 10.1136/ijgc-2022-003799.
3
Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer.用于预测高级别浆液性卵巢癌最佳肿瘤细胞减灭术的综合临床和基因组模型
Cancers (Basel). 2022 Jul 21;14(14):3554. doi: 10.3390/cancers14143554.
4
Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort.个性化治疗队列中卵巢癌初次肿瘤细胞减灭术与新辅助化疗的生存比较
Front Oncol. 2021 Feb 10;10:632195. doi: 10.3389/fonc.2020.632195. eCollection 2020.
5
Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.适当的分诊可进行积极的初次肿瘤细胞减灭术,其发病率和死亡率与化疗后间隔手术相当。
Gynecol Oncol. 2021 Mar;160(3):681-687. doi: 10.1016/j.ygyno.2020.12.026. Epub 2020 Dec 31.
6
Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk?晚期卵巢癌新辅助化疗分诊实用指南:高风险,高回报……还是风险过高?
Gynecol Oncol. 2020 Jun;157(3):561-562. doi: 10.1016/j.ygyno.2020.05.003.

本文引用的文献

1
Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.采用基于证据的分诊算法降低高级别上皮性卵巢癌初次肿瘤细胞减灭术后 90 天死亡率。
Gynecol Oncol. 2019 Oct;155(1):58-62. doi: 10.1016/j.ygyno.2019.08.004. Epub 2019 Aug 8.
2
Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.高级别浆液性卵巢癌肿瘤细胞减灭术90天死亡率作为报告参数
Obstet Gynecol. 2017 Aug;130(2):305-314. doi: 10.1097/AOG.0000000000002140.
3
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.一项III期随机试验(日本临床肿瘤学组研究JCOG0602)中,新辅助化疗后,III/IV期卵巢癌、输卵管癌和腹膜癌的初始肿瘤细胞减灭术与间隔肿瘤细胞减灭术之间治疗侵袭性的比较
Eur J Cancer. 2016 Sep;64:22-31. doi: 10.1016/j.ejca.2016.05.017. Epub 2016 Jun 17.
4
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.比较原发性手术与新辅助化疗治疗高肿瘤负荷晚期上皮性卵巢癌的III期随机临床试验(SCORPION试验):围手术期结局的最终分析
Eur J Cancer. 2016 May;59:22-33. doi: 10.1016/j.ejca.2016.01.017. Epub 2016 Mar 19.
5
Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.原发性肿瘤细胞减灭术后晚期卵巢癌严重术后并发症的风险预测模型。
Gynecol Oncol. 2016 Jan;140(1):15-21. doi: 10.1016/j.ygyno.2015.10.025. Epub 2015 Nov 2.
6
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.新诊断的晚期卵巢癌的初次化疗与初次手术(CHORUS):一项开放标签、随机、对照、非劣效性试验。
Lancet. 2015 Jul 18;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6. Epub 2015 May 19.
7
Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery.高级卵巢癌细胞减灭术后术后发病率的预测因素:上腹部手术并发症的分析与处理。
Gynecol Oncol. 2015 Jun;137(3):406-11. doi: 10.1016/j.ygyno.2015.03.043. Epub 2015 Mar 28.
8
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).分析同期接受根治性手术(PDS)与新辅助化疗(NACT)随机 EORTC-NCIC 试验的大块晚期卵巢、输卵管和腹膜癌患者。
Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.
9
Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.结构化质量管理方案对原发性晚期卵巢癌手术结局的影响。
Gynecol Oncol. 2011 Jun 1;121(3):615-9. doi: 10.1016/j.ygyno.2011.02.014. Epub 2011 Mar 17.
10
Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.识别传统卵巢癌治疗方法中风险最高的患者群体。
Gynecol Oncol. 2011 Jan;120(1):23-8. doi: 10.1016/j.ygyno.2010.09.010. Epub 2010 Oct 8.

在识别晚期卵巢癌中最不适合细胞减灭术的患者时,减少猜测,增加证据:一种个体化手术管理的分诊算法。

Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.

机构信息

Department of Obstetrics and Gynecology, Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, United States.

Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States.

出版信息

Gynecol Oncol. 2020 Jun;157(3):572-577. doi: 10.1016/j.ygyno.2020.03.024. Epub 2020 Apr 1.

DOI:10.1016/j.ygyno.2020.03.024
PMID:32247602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7293555/
Abstract

OBJECTIVE

We previously reported an algorithm that identifies women at high risk of postoperative morbidity & mortality (M/M) as a tool to triage between neoadjuvant chemotherapy and primary surgery for epithelial ovarian cancer (EOC). We sought to independently validate its performance using multicenter data.

METHODS

Women who underwent surgery for stage IIIC/IV EOC between 1/1/2014 and 12/31/2017 were identified from the National Surgical Quality Improvement Program database and classified as "high risk" or "triage appropriate" using our algorithm. Outcomes were compared between triage appropriate and high-risk women using the chi-square test.

RESULTS

1777 women met inclusion criteria; the mean age was 62.6 years and 81.9% had stage IIIC disease. Nationally, the surgical complexity scores were low (69.8% low, 25.2% intermediate and 5.0% high). "High risk" women had 2-fold higher rate of severe 30-day complication or death (6.2% vs 3.5%; p = 0.01), a 3-fold higher rate of 30-day mortality (1.4% vs 0.5%; p = 0.08), and a higher risk of death following a severe complication (11.1% vs. 0%, p = 0.11). A sensitivity analysis excluding women with unknown albumin who didn't meet other high risk criteria showed similar results: severe 30-day complications or death (6.2% vs 3.5%; p = 0.02) and 30-day mortality (1.4% vs 0.3%; p = 0.04) for "high risk" vs "triage appropriate" women.

CONCLUSIONS

Primary cytoreductive surgery to minimal residual disease remains the goal for EOC. We verify that our algorithm can identify women at risk of M/M using national multicenter data, despite a low complexity surgical setting and using 30-day mortality (vs. 90-day). Objective surgical risk assessment for ovarian cancer should be standard of care and can be incorporated into practice using the Mayo triage algorithm.

摘要

目的

我们之前报道了一种算法,该算法可识别术后发病率和死亡率高的女性(M/M),作为对上皮性卵巢癌(EOC)新辅助化疗和直接手术进行分类的工具。我们试图使用多中心数据独立验证其性能。

方法

从国家手术质量改进计划数据库中确定了 2014 年 1 月 1 日至 2017 年 12 月 31 日接受 IIIC/IV 期 EOC 手术的女性,并使用我们的算法将其分类为“高风险”或“分诊适当”。使用卡方检验比较分诊适当和高风险女性之间的结局。

结果

1777 名女性符合纳入标准;平均年龄为 62.6 岁,81.9%为 IIIIC 期疾病。全国范围内,手术复杂程度评分较低(69.8%为低,25.2%为中,5.0%为高)。“高风险”女性严重 30 天并发症或死亡的发生率高 2 倍(6.2% vs 3.5%;p=0.01),30 天死亡率高 3 倍(1.4% vs 0.5%;p=0.08),严重并发症后死亡风险较高(11.1% vs. 0%,p=0.11)。排除不符合其他高风险标准且白蛋白未知的女性进行敏感性分析,结果相似:严重 30 天并发症或死亡(6.2% vs 3.5%;p=0.02)和 30 天死亡率(1.4% vs 0.3%;p=0.04),高风险女性 vs 分诊适当女性。

结论

达到最小残留疾病的主要细胞减灭术仍然是 EOC 的目标。我们使用全国多中心数据验证了我们的算法可以识别有发生 M/M 风险的女性,尽管手术难度低且使用 30 天死亡率(而非 90 天)。卵巢癌的客观手术风险评估应成为标准护理,并可使用 Mayo 分诊算法将其纳入实践。